显示样式:     当前分类: 医药    当前期刊: Nature Reviews Drug Discovery    加入关注    导出
我的关注
我的收藏
您暂时未登录!
登录
  • Emptying the stores: lysosomal diseases and therapeutic strategies
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 2017-11-17
    Frances M. Platt

    Emptying the stores: lysosomal diseases and therapeutic strategies Emptying the stores: lysosomal diseases and therapeutic strategies, Published online: 17 November 2017; doi:10.1038/nrd.2017.214 NatureArticleSnippet(type=short-summary, markup= Lysosomal storage disorders (LSDs) are rare, inherited metabolic disorders that result from defects in lysosomal function, for which treatment options are limited. Here, Platt provides an overview of LSDs, approved and potential therapeutic approaches and agents currently in development. The challenges associated with LSD diagnosis, drug development and treatment are discussed. , isJats=true)

    更新日期:2017-11-17
  • Metabolic disease: Ectopic olfactory receptor activation reverses obesity
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 2017-11-17
    Sarah Crunkhorn

    Metabolic disease: Ectopic olfactory receptor activation reverses obesity Metabolic disease: Ectopic olfactory receptor activation reverses obesity, Published online: 17 November 2017; doi:10.1038/nrd.2017.230

    更新日期:2017-11-17
  • Eric Rubin
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 2017-11-17

    Eric Rubin Eric Rubin, Published online: 17 November 2017; doi:10.1038/nrd.2017.228 NatureArticleSnippet(type=short-summary, markup= Eric Rubin, vice president of clinical oncology at Merck & Co, discusses tumour-agnostic approvals, immunotherapy combinations and the modernization of clinical trial eligibility criteria. , isJats=true)

    更新日期:2017-11-17
  • Sepsis: Stalking a new target
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 2017-11-17
    Katie Kingwell

    Sepsis: Stalking a new target Sepsis: Stalking a new target, Published online: 17 November 2017; doi:10.1038/nrd.2017.238

    更新日期:2017-11-17
  • Cancer: Bispecific antibody directs T cells to solid tumours
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 2017-11-17
    Megan Cully

    Cancer: Bispecific antibody directs T cells to solid tumours Cancer: Bispecific antibody directs T cells to solid tumours, Published online: 17 November 2017; doi:10.1038/nrd.2017.237

    更新日期:2017-11-17
  • Emptying the stores: lysosomal diseases and therapeutic strategies
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 2017-11-17
    Frances M. Platt

    Emptying the stores: lysosomal diseases and therapeutic strategies Emptying the stores: lysosomal diseases and therapeutic strategies, Published online: 17 November 2017; doi:10.1038/nrd.2017.214 NatureArticleSnippet(type=short-summary, markup= Lysosomal storage disorders (LSDs) are rare, inherited metabolic disorders that result from defects in lysosomal function, for which treatment options are limited. Here, Platt provides an overview of LSDs, approved and potential therapeutic approaches and agents currently in development. The challenges associated with LSD diagnosis, drug development and treatment are discussed. , isJats=true)

    更新日期:2017-11-17
  • Metabolic disease: Ectopic olfactory receptor activation reverses obesity
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 2017-11-17
    Sarah Crunkhorn

    Metabolic disease: Ectopic olfactory receptor activation reverses obesity Metabolic disease: Ectopic olfactory receptor activation reverses obesity, Published online: 17 November 2017; doi:10.1038/nrd.2017.230

    更新日期:2017-11-17
  • Eric Rubin
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 2017-11-17

    Eric Rubin Eric Rubin, Published online: 17 November 2017; doi:10.1038/nrd.2017.228 NatureArticleSnippet(type=short-summary, markup= Eric Rubin, vice president of clinical oncology at Merck & Co, discusses tumour-agnostic approvals, immunotherapy combinations and the modernization of clinical trial eligibility criteria. , isJats=true)

    更新日期:2017-11-17
  • Sepsis: Stalking a new target
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 2017-11-17
    Katie Kingwell

    Sepsis: Stalking a new target Sepsis: Stalking a new target, Published online: 17 November 2017; doi:10.1038/nrd.2017.238

    更新日期:2017-11-17
  • Cancer: Bispecific antibody directs T cells to solid tumours
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 2017-11-17
    Megan Cully

    Cancer: Bispecific antibody directs T cells to solid tumours Cancer: Bispecific antibody directs T cells to solid tumours, Published online: 17 November 2017; doi:10.1038/nrd.2017.237

    更新日期:2017-11-17
  • The atopic dermatitis market
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 2017-11-06
    Eleni Pantazi, Gianluca Valenza, Manuela Hess, Bashar Hamad

    The atopic dermatitis marketThe atopic dermatitis market, Published online: 06 November 2017; doi:10.1038/nrd.2017.192NatureArticleSnippet(type=short-summary, markup=The market for atopic dermatitis therapies is dominated by topical corticosteroids, but is poised to change with the recent approvals of dupilumab and crisaborole, as well as other drugs in clinical development., isJats=true)

    更新日期:2017-11-10
  • JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 2017-11-06
    Daniella M. Schwartz, Yuka Kanno, Alejandro Villarino, Michael Ward, Massimo Gadina, John J. O'Shea

    JAK inhibition as a therapeutic strategy for immune and inflammatory diseasesJAK inhibition as a therapeutic strategy for immune and inflammatory diseases, Published online: 06 November 2017; doi:10.1038/nrd.2017.201NatureArticleSnippet(type=short-summary, markup=Janus kinases (JAKs) are essential signalling mediators downstream of many pro-inflammatory cytokines. Jakinibs — small-molecule inhibitors of JAKs — have gained traction as safe and efficacious options for the treatment of inflammation-driven pathologies. This Review discusses the biology, development and efficacy of jakinibs in the treatment of immune and inflammatory diseases., isJats=true)

    更新日期:2017-11-10
  • Respiratory diseases: Gq protein inhibition induces airway relaxation
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 2017-10-30
    Sarah Crunkhorn

    Respiratory diseases: Gq protein inhibition induces airway relaxationRespiratory diseases: Gq protein inhibition induces airway relaxation, Published online: 30 October 2017; doi:10.1038/nrd.2017.203

    更新日期:2017-11-10
  • G protein-coupled receptors: Gut feeling on bacterial GPCR agonists
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 2017-10-30
    Megan Cully

    G protein-coupled receptors: Gut feeling on bacterial GPCR agonistsG protein-coupled receptors: Gut feeling on bacterial GPCR agonists, Published online: 30 October 2017; doi:10.1038/nrd.2017.205

    更新日期:2017-11-10
  • Transplantation: Combining OX40L and mTOR blockade
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 2017-10-30
    Sarah Crunkhorn

    Transplantation: Combining OX40L and mTOR blockadeTransplantation: Combining OX40L and mTOR blockade, Published online: 30 October 2017; doi:10.1038/nrd.2017.207

    更新日期:2017-11-10
  • Cancer: Reducing melanoma in redheads
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 2017-10-30
    Sarah Crunkhorn

    Cancer: Reducing melanoma in redheadsCancer: Reducing melanoma in redheads, Published online: 30 October 2017; doi:10.1038/nrd.2017.209

    更新日期:2017-11-10
  • Preclinical antibiotic pipeline gets a pick-me-up
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 2017-10-30
    Asher Mullard

    Preclinical antibiotic pipeline gets a pick-me-upPreclinical antibiotic pipeline gets a pick-me-up, Published online: 30 October 2017; doi:10.1038/nrd.2017.213NatureArticleSnippet(type=short-summary, markup=CARB-X, a public–private partnership aimed at bolstering the antibiotic pipeline, funded a diverse set of 17 early-stage drug development projects in its first year., isJats=true)

    更新日期:2017-11-10
  • Nora Volkow
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 2017-10-30

    Nora VolkowNora Volkow, Published online: 30 October 2017; doi:10.1038/nrd.2017.215NatureArticleSnippet(type=short-summary, markup=Nora Volkow, director of the National Institute on Drug Abuse (NIDA), discusses her ambitious aim of halving the time needed to develop non-opioid analgesics and anti-addiction drugs., isJats=true)

    更新日期:2017-11-10
  • The atopic dermatitis market
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 2017-11-06
    Eleni Pantazi, Gianluca Valenza, Manuela Hess, Bashar Hamad

    The atopic dermatitis marketThe atopic dermatitis market, Published online: 06 November 2017; doi:10.1038/nrd.2017.192NatureArticleSnippet(type=short-summary, markup=The market for atopic dermatitis therapies is dominated by topical corticosteroids, but is poised to change with the recent approvals of dupilumab and crisaborole, as well as other drugs in clinical development., isJats=true)

    更新日期:2017-11-06
  • JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 2017-11-06
    Daniella M. Schwartz, Yuka Kanno, Alejandro Villarino, Michael Ward, Massimo Gadina, John J. O'Shea

    The discovery of cytokines as key drivers of immune-mediated diseases has spurred efforts to target their associated signalling pathways. Janus kinases (JAKs) are essential signalling mediators downstream of many pro-inflammatory cytokines, and small-molecule inhibitors of JAKs (jakinibs) have gained traction as safe and efficacious options for the treatment of inflammation-driven pathologies such as rheumatoid arthritis, psoriasis and inflammatory bowel disease. Building on the clinical success of first-generation jakinibs, second-generation compounds that claim to be more selective are currently undergoing development and proceeding to clinical trials. However, important questions remain about the advantages and limitations of improved JAK selectivity, optimal routes and dosing regimens and how best to identify patients who will benefit from jakinibs. This Review discusses the biology of jakinibs from a translational perspective, focusing on recent insights from clinical trials, the development of novel agents and the use of jakinibs in a spectrum of immune and inflammatory diseases.

    更新日期:2017-11-06
  • Respiratory diseases: Gq protein inhibition induces airway relaxation
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 2017-10-30
    Sarah Crunkhorn

    Respiratory diseases: Gq protein inhibition induces airway relaxation Nature Reviews Drug Discovery, Published online: 30 October 2017; doi:10.1038/nrd.2017.203

    更新日期:2017-10-30
  • G protein-coupled receptors: Gut feeling on bacterial GPCR agonists
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 2017-10-30
    Megan Cully

    G protein-coupled receptors: Gut feeling on bacterial GPCR agonists Nature Reviews Drug Discovery, Published online: 30 October 2017; doi:10.1038/nrd.2017.205

    更新日期:2017-10-30
  • Transplantation: Combining OX40L and mTOR blockade
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 2017-10-30
    Sarah Crunkhorn

    Transplantation: Combining OX40L and mTOR blockade Nature Reviews Drug Discovery, Published online: 30 October 2017; doi:10.1038/nrd.2017.207

    更新日期:2017-10-30
  • Cancer: Reducing melanoma in redheads
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 2017-10-30
    Sarah Crunkhorn

    Cancer: Reducing melanoma in redheads Nature Reviews Drug Discovery, Published online: 30 October 2017; doi:10.1038/nrd.2017.209

    更新日期:2017-10-30
  • Preclinical antibiotic pipeline gets a pick-me-up
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 2017-10-30
    Asher Mullard

    Preclinical antibiotic pipeline gets a pick-me-up Nature Reviews Drug Discovery, Published online: 30 October 2017; doi:10.1038/nrd.2017.213 CARB-X, a public–private partnership aimed at bolstering the antibiotic pipeline, funded a diverse set of 17 early-stage drug development projects in its first year.

    更新日期:2017-10-30
  • Nora Volkow
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 2017-10-30

    Nora Volkow Nature Reviews Drug Discovery, Published online: 30 October 2017; doi:10.1038/nrd.2017.215 Nora Volkow, director of the National Institute on Drug Abuse (NIDA), discusses her ambitious aim of halving the time needed to develop non-opioid analgesics and anti-addiction drugs.

    更新日期:2017-10-30
  • $215 million cancer immunotherapy biomarker consortium debuts
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 2017-10-30
    Asher Mullard

    $215 million cancer immunotherapy biomarker consortium debuts Nature Reviews Drug Discovery, Published online: 30 October 2017; doi:10.1038/nrd.2017.223

    更新日期:2017-10-30
  • Emerging therapies for idiopathic pulmonary fibrosis, a progressive age-related disease
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 2017-10-30
    Ana L. Mora, Mauricio Rojas, Annie Pardo, Moises Selman

    Emerging therapies for idiopathic pulmonary fibrosis, a progressive age-related disease Nature Reviews Drug Discovery, Published online: 30 October 2017; doi:10.1038/nrd.2017.225

    更新日期:2017-10-30
  • $215 million cancer immunotherapy biomarker consortium debuts
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 2017-10-30
    Asher Mullard

    $215 million cancer immunotherapy biomarker consortium debuts Nature Reviews Drug Discovery, Published online: 30 October 2017; doi:10.1038/nrd.2017.223

    更新日期:2017-10-30
  • Emerging therapies for idiopathic pulmonary fibrosis, a progressive age-related disease
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 2017-10-30
    Ana L. Mora, Mauricio Rojas, Annie Pardo, Moises Selman

    Emerging therapies for idiopathic pulmonary fibrosis, a progressive age-related disease Nature Reviews Drug Discovery, Published online: 30 October 2017; doi:10.1038/nrd.2017.225

    更新日期:2017-10-30
  • Trial watch: Tracing investment in drug development for Alzheimer disease
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 2017-10-23
    Alpha Tom Kodamullil, Firas Zekri, Meemansa Sood, Bastian Hengerer, Luc Canard, Duncan McHale, Martin Hofmann-Apitius

    Trial watch: Tracing investment in drug development for Alzheimer disease Nature Reviews Drug Discovery, Published online: 23 October 2017; doi:10.1038/nrd.2017.169

    更新日期:2017-10-23
  • Bispecific antibody pipeline moves beyond oncology
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 
    Asher Mullard

    Bispecific antibody pipeline moves beyond oncology Nature Reviews Drug Discovery, Published online: 13 October 2017; doi:10.1038/nrd.2017.211

    更新日期:2017-10-13
  • Legacy data sharing to improve drug safety assessment: the eTOX project
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 
    Ferran Sanz, François Pognan, Thomas Steger-Hartmann, Carlos Díaz, eTOX, Montserrat Cases, Manuel Pastor, Philippe Marc, Joerg Wichard, Katharine Briggs, David K. Watson, Thomas Kleinöder, Chihae Yang, Alexander Amberg, Maria Beaumont, Anthony J. Brookes, Søren Brunak, Mark T. D. Cronin, Gerhard F. Ecker, Sylvia Escher, Nigel Greene, Antonio Guzmán, Anne Hersey, Pascale Jacques, Lieve Lammens, Jordi Mestres, Wolfgang Muster, Helle Northeved, Marc Pinches, Javier Saiz, Nicolas Sajot, Alfonso Valencia, Johan van der Lei, Nico P. E. Vermeulen, Esther Vock, Gerhard Wolber, Ismael Zamora

    The sharing of legacy preclinical safety data among pharmaceutical companies and its integration with other information sources offers unprecedented opportunities to improve the early assessment of drug safety. Here, we discuss the experience of the eTOX project, which was established through the Innovative Medicines Initiative to explore this possibility.

    更新日期:2017-10-13
  • WD40 repeat domain proteins: a novel target class?
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 
    Matthieu Schapira, Mike Tyers, Maricel Torrent, Cheryl H. Arrowsmith

    Antagonism of protein–protein interactions (PPIs) with small molecules is becoming more feasible as a therapeutic approach. Successful PPI inhibitors tend to target proteins containing deep peptide-binding grooves or pockets rather than the more common large, flat protein interaction surfaces. Here, we review one of the most abundant PPI domains in the human proteome, the WD40 repeat (WDR) domain, which has a central peptide-binding pocket and is a member of the β-propeller domain-containing protein family. Recently, two WDR domain-containing proteins, WDR5 and EED, as well as other β-propeller domains have been successfully targeted by potent, specific, cell-active, drug-like chemical probes. Could WDR domains be a novel target class for drug discovery? Although the research is at an early stage and therefore not clinically validated, cautious optimism is justified, as WDR domain-containing proteins are involved in multiple disease-associated pathways. The druggability and structural diversity of WDR domain binding pockets suggest that understanding how to target this prevalent domain class will open up areas of disease biology that have so far resisted drug discovery efforts.

    更新日期:2017-10-13
  • Tau-based therapies in neurodegeneration: opportunities and challenges
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 
    Chuanzhou Li, Jürgen Götz

    Aggregates of the microtubule-associated protein tau are a defining feature of several neurodegenerative diseases that are collectively known as tauopathies, and constitute one of the hallmark lesions of Alzheimer disease (AD). Given the lack of efficacy to date of amyloid-β-targeted therapies for AD, interest is growing in tau as a potential alternative target. Several drug candidates, which are now in clinical trials, aim to reduce tau levels or to prevent the aggregation or pathological post-translation modifications of this protein. In this Review, we discuss preclinical and clinical studies in light of an increased understanding of the physiological and pathological roles of tau, advances in animal models of tauopathy, the identification of novel targets and the availability of novel tracers to track tau.

    更新日期:2017-10-11
  • Market watch: Innovation in the preclinical antibiotic pipeline
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 
    Ursula Theuretzbacher, Miloje Savic, Christine Årdal, Kevin Outterson

    Market watch: Innovation in the preclinical antibiotic pipeline Nature Reviews Drug Discovery, Published online: 6 October 2017; doi:10.1038/nrd.2017.195

    更新日期:2017-10-11
  • Breaking barriers to novel analgesic drug development
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 
    Ajay S. Yekkirala, David P. Roberson, Bruce P. Bean, Clifford J. Woolf

    Breaking barriers to novel analgesic drug development Nature Reviews Drug Discovery, Published online: 6 October 2017; doi:10.1038/nrd.2017.202

    更新日期:2017-10-11
  • Emerging therapies for idiopathic pulmonary fibrosis, a progressive age-related disease
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 
    Ana L. Mora, Mauricio Rojas, Annie Pardo, Moises Selman

    Idiopathic pulmonary fibrosis (IPF) is a fatal age-associated disease that is characterized by progressive and irreversible scarring of the lung. The pathogenesis of IPF is not completely understood and current therapies are limited to those that reduce the rate of functional decline in patients with mild-to-moderate disease. In this context, new therapeutic approaches that substantially improve the survival time and quality of life of these patients are urgently needed. Our incomplete understanding of the pathogenic mechanisms of IPF and the lack of appropriate experimental models that reproduce the key characteristics of the human disease are major challenges. As ageing is a major risk factor for IPF, age-related cell perturbations such as telomere attrition, senescence, epigenetic drift, stem cell exhaustion, loss of proteostasis and mitochondrial dysfunction are becoming targets of interest for IPF therapy. In this Review, we discuss current and emerging therapies for IPF, particularly those targeting age-related mechanisms, and discuss future therapeutic approaches.

    更新日期:2017-10-11
  • Bispecific antibody pipeline moves beyond oncology
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 
    Asher Mullard

    Bispecific antibody pipeline moves beyond oncology Nature Reviews Drug Discovery, Published online: 29 September 2017; doi:10.1038/nrd.2017.187 The FDA could soon approve the first bispecific antibody for a non-oncology indication, but clinical applications that make full use of the biological opportunity afforded by the nascent modality remain rare.

    更新日期:2017-10-11
  • Neurodevelopmental disorders: Epigenetic targets on the table
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 
    Katie Kingwell

    Neurodevelopmental disorders: Epigenetic targets on the table Nature Reviews Drug Discovery, Published online: 29 September 2017; doi:10.1038/nrd.2017.193

    更新日期:2017-10-11
  • CETP inhibitors stumble on
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 
    Asher Mullard

    CETP inhibitors stumble on Nature Reviews Drug Discovery, Published online: 29 September 2017; doi:10.1038/nrd.2017.197

    更新日期:2017-10-11
  • Cancer: Beyond the C
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 
    Ulrike Harjes

    Cancer: Beyond the C Nature Reviews Drug Discovery, Published online: 29 September 2017; doi:10.1038/nrd.2017.200

    更新日期:2017-10-11
  • Synthetic lethality screens point the way to new cancer drug targets
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 
    Asher Mullard

    Synthetic lethality screens point the way to new cancer drug targets Nature Reviews Drug Discovery, Published online: 22 September 2017; doi:10.1038/nrd.2017.190

    更新日期:2017-09-25
  • Neurodegenerative disease: DLK zips across neurodegeneration
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 
    M. Teresa Villanueva

    Neurodegenerative disease: DLK zips across neurodegeneration Nature Reviews Drug Discovery, Published online: 22 September 2017; doi:10.1038/nrd.2017.180

    更新日期:2017-09-22
  • RNA-based therapeutics: Increasing efficacy
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 
    Sarah Crunkhorn

    RNA-based therapeutics: Increasing efficacy Nature Reviews Drug Discovery, Published online: 22 September 2017; doi:10.1038/nrd.2017.182

    更新日期:2017-09-22
  • Infectious disease: Blocking malaria transmission
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 
    Sarah Crunkhorn

    Infectious disease: Blocking malaria transmission Nature Reviews Drug Discovery, Published online: 22 September 2017; doi:10.1038/nrd.2017.184

    更新日期:2017-09-22
  • Biometric monitoring devices for assessing end points in clinical trials: developing an ecosystem
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 
    Stephen P. Arnerić, Jesse M. Cedarbaum, Sean Khozin, Spyros Papapetropoulos, Derek L. Hill, Michael Ropacki, Jane Rhodes, Penny A. Dacks, Lynn D. Hudson, Mark Forrest Gordon, Volker D. Kern, Klaus Romero, George Vradenburg, Rhoda Au, Daniel R. Karlin, Maurizio F. Facheris, Cheryl J. Fitzer-Attas, Ottavio V. Vitolo, Jian Wang, Bradley M. Miller, Jeffrey A. Kaye

    Biometric monitoring devices for assessing end points in clinical trials: developing an ecosystem Nature Reviews Drug Discovery, Published online: 22 September 2017; doi:10.1038/nrd.2017.153

    更新日期:2017-09-22
  • Autoimmune disease: LKB1 helps Treg cells battle exhaustion
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 
    Megan Cully

    Autoimmune disease: LKB1 helps Treg cells battle exhaustion Nature Reviews Drug Discovery, Published online: 22 September 2017; doi:10.1038/nrd.2017.188

    更新日期:2017-09-22
  • Neurological disorders: Reversing Rett syndrome
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 
    Sarah Crunkhorn

    Neurological disorders: Reversing Rett syndrome Nature Reviews Drug Discovery, Published online: 22 September 2017; doi:10.1038/nrd.2017.181

    更新日期:2017-09-22
  • CNS injury: Promoting neural repair
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 
    Sarah Crunkhorn

    CNS injury: Promoting neural repair Nature Reviews Drug Discovery, Published online: 22 September 2017; doi:10.1038/nrd.2017.183

    更新日期:2017-09-22
  • Market watch: Upcoming market catalysts in Q4 2017
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 
    Gregory Pak

    Market watch: Upcoming market catalysts in Q4 2017 Nature Reviews Drug Discovery, Published online: 15 September 2017; doi:10.1038/nrd.2017.185

    更新日期:2017-09-18
  • The human microbiome: opportunity or hype?
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 2017-09-15
    Pedro M. Valencia, Magali Richard, Jesse Brock, Elsy Boglioli

    The human microbiome: opportunity or hype? Nature Reviews Drug Discovery, Published online: 15 September 2017; doi:10.1038/nrd.2017.154 This article discusses investment in microbiome-based therapeutic approaches and key questions for the field related to the underlying science, clinical development, regulation and business models.

    更新日期:2017-09-18
  • Synthetic lethality screens point the way to new cancer drug targets
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 
    Asher Mullard

    Synthetic lethality screens point the way to new cancer drug targets Nature Reviews Drug Discovery, Published online: 15 September 2017; doi:10.1038/nrd.2017.189

    更新日期:2017-09-18
  • Patent watch: The evolving intellectual property landscape for pruritus therapies
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 
    Benjamin Leung, Drew Lowery

    Patent watch: The evolving intellectual property landscape for pruritus therapies Nature Reviews Drug Discovery, Published online: 8 September 2017; doi:10.1038/nrd.2017.161

    更新日期:2017-09-09
  • Cancer: Ironing it out
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 
    Ulrike Harjes

    Cancer: Ironing it out Nature Reviews Drug Discovery, Published online: 1 September 2017; doi:10.1038/nrd.2017.168

    更新日期:2017-09-07
  • Nigel Blackburn
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 

    Nigel Blackburn Nature Reviews Drug Discovery, Published online: 1 September 2017; doi:10.1038/nrd.2017.172 Nigel Blackburn, Director of drug development at CRUK, discusses the charity's changing approach to bolstering the cancer drug pipeline.

    更新日期:2017-09-07
  • FDA approves first-in-class cancer metabolism drug
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 
    Asher Mullard

    FDA approves first-in-class cancer metabolism drug Nature Reviews Drug Discovery, Published online: 1 September 2017; doi:10.1038/nrd.2017.174

    更新日期:2017-09-07
  • FDA rejects first-in-class osteoporosis drug
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 
    Asher Mullard

    FDA rejects first-in-class osteoporosis drug Nature Reviews Drug Discovery, Published online: 1 September 2017; doi:10.1038/nrd.2017.176

    更新日期:2017-09-07
  • Flexibility in the FDA approach to orphan drug development
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 2017-09-01
    Nina L. Hunter, Gayatri R. Rao, Rachel E. Sherman

    Flexibility in the FDA approach to orphan drug development Nature Reviews Drug Discovery, Published online: 1 September 2017; doi:10.1038/nrd.2017.151 Scientific advances, in combination with government incentives and commercial opportunity, have fuelled strong investment in orphan drugs, resulting in many innovative therapies. Here, we discuss the approach of the FDA to a range of issues that remain crucial to maintaining this momentum, such as the use of the totality of evidence in evaluating orphan drugs.

    更新日期:2017-09-07
  • Synthetic lethality screens point the way to new cancer drug targets
    Nat. Rev. Drug. Disc. (IF 57) Pub Date : 
    Asher Mullard

    Synthetic lethality screens point the way to new cancer drug targets Nature Reviews Drug Discovery, Published online: 1 September 2017; doi:10.1038/nrd.2017.165 A resurgence in synthetic lethality screening, enabled by CRISPR gene editing, is unlocking targeted drugs for patients with cancerous loss-of-function mutations.

    更新日期:2017-09-07
Some contents have been Reproduced with permission of the American Chemical Society.
Some contents have been Reproduced by permission of The Royal Society of Chemistry.
所有期刊列表A-Z